PURPOSE: To compare the pharmacokinetics (PK) of MNRP1685A, a human monoclonal antibody (mAb) against neuropilin-1 (NRP1), in mice, rats, monkeys, and cancer patients from a Phase I study to model with parallel linear and nonlinear clearances. METHODS: Binding characteristics of MNRP1685A in different species were evaluated using surface plasmon resonance technology. PK profiles of MNRP1685A after single and/or multiple doses in different species were analyzed using population analysis. PK parameters were compared across species. RESULTS: MNRP1685A binds to NRP1 in all four species tested. Consistent with the wide expression of NRP1, MNRP1685A demonstrated pronounced non-linear PK over a wide dose range. PK profiles are best described by a two-compartment model with parallel linear and nonlinear clearances. Model-derived PK parameters suggest similar in-vivo target expression levels and binding affinity to target across all species tested. However, compared to typical human/humanized mAbs, non-specific clearance of MNRP1685A was faster in mice, rats, and humans (60.3, 19.4, and 8.5 ml/day/kg), but not in monkeys (3.22 ml/day/kg). CONCLUSIONS: Monkey PK properly predicted the target-mediated clearance of MNRP1685A but underestimated its non-specific clearance in humans. This unique PK property warrants further investigation of underlying mechanisms.
PURPOSE: To compare the pharmacokinetics (PK) of MNRP1685A, a human monoclonal antibody (mAb) against neuropilin-1 (NRP1), in mice, rats, monkeys, and cancerpatients from a Phase I study to model with parallel linear and nonlinear clearances. METHODS: Binding characteristics of MNRP1685A in different species were evaluated using surface plasmon resonance technology. PK profiles of MNRP1685A after single and/or multiple doses in different species were analyzed using population analysis. PK parameters were compared across species. RESULTS: MNRP1685A binds to NRP1 in all four species tested. Consistent with the wide expression of NRP1, MNRP1685A demonstrated pronounced non-linear PK over a wide dose range. PK profiles are best described by a two-compartment model with parallel linear and nonlinear clearances. Model-derived PK parameters suggest similar in-vivo target expression levels and binding affinity to target across all species tested. However, compared to typical human/humanized mAbs, non-specific clearance of MNRP1685A was faster in mice, rats, and humans (60.3, 19.4, and 8.5 ml/day/kg), but not in monkeys (3.22 ml/day/kg). CONCLUSIONS: Monkey PK properly predicted the target-mediated clearance of MNRP1685A but underestimated its non-specific clearance in humans. This unique PK property warrants further investigation of underlying mechanisms.
Authors: M L Gagnon; D R Bielenberg; Z Gechtman; H Q Miao; S Takashima; S Soker; M Klagsbrun Journal: Proc Natl Acad Sci U S A Date: 2000-03-14 Impact factor: 11.205
Authors: Daniela Bumbaca; Anne Wong; Elizabeth Drake; Arthur E Reyes; Benjamin C Lin; Jean-Philippe Stephan; Luc Desnoyers; Ben-Quan Shen; Mark S Dennis Journal: MAbs Date: 2011-07-01 Impact factor: 5.857
Authors: Donna E Hansel; Robert E Wilentz; Charles J Yeo; Richard D Schulick; Elizabeth Montgomery; Anirban Maitra Journal: Am J Surg Pathol Date: 2004-03 Impact factor: 6.394
Authors: Xiangdan Wang; Valerie Quarmby; Carl Ng; Anan Chuntharapai; Theresa Shek; Charles Eigenbrot; Robert F Kelley; Steven Shia; Krista McCutcheon; John Lowe; Cecilia Leddy; Kyle Coachman; Gary Cain; Felix Chu; Isidro Hotzel; Mauricio Maia; Eric Wakshull; Jihong Yang Journal: MAbs Date: 2013-04-29 Impact factor: 5.857
Authors: Yan Xin; Hong Xiang; Denise Jin; Frank-Peter Theil; Amita Joshi; Lisa A Damico-Beyer; Shuang Bai Journal: J Pharmacokinet Pharmacodyn Date: 2012-03-01 Impact factor: 2.745
Authors: Colin D Weekes; Muralidhar Beeram; Anthony W Tolcher; Kyriakos P Papadopoulos; Lia Gore; Priti Hegde; Yan Xin; Ron Yu; L Mason Shih; Hong Xiang; Rainer K Brachmann; Amita Patnaik Journal: Invest New Drugs Date: 2014-03-07 Impact factor: 3.850